FDA
-
-
-
-
-
-
-
Gain Therapeutics to Present at the 38th Annual ROTH Conference
-
-
-
-
-
-
-
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
-
-
-
-
-
-
-
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
-
-
-
-
-
-
-
Gain Therapeutics gets Australian approval for Phase 1b trial extension
-
-
-
-
-
-
-
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
-
-
-
-
-
-
-
Gain Therapeutics (GANX) CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
-
-
-
-
-
-
-
Gain Therapeutics' (GANX) GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
-
323,584 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

